About CSL Behring
CSL Behring is a company based in King Of Prussia (United States) founded in 2009. CSL Behring has completed 2 acquisitions, including Calimmune and Vitaeris.
- Headquarter King Of Prussia, United States
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website cslbehring.com
- Social LinkedIn X
Funding Insights of CSL Behring
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of CSL Behring with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | – | Grant | – | – |
1 investors in total: 1 institutional.
Investors in CSL Behring
CSL Behring has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for CSL Behring
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CSL Behring
425 people are tracked at CSL Behring (207 in leadership, 8 in board & advisors, 210 in team).
| Name | Role | Group |
|---|---|---|
Diego Sacristan | Head Of International; CSL Behring | Leadership |
Matt Tripp | Senior Financial Business Partner | Leadership |
Jordi Pont Arnaiz | Associate Director Sales & Marketing Commercial Spain | Leadership |
Farana Power | Executive Assistant To VP Of Commercial Operations - International Markets And Pandemic | Leadership |
Keely Beck Zipp | Vice President, Immunoglobulins TA & Global Commercial Development Portfolio Planning | Leadership |
Jessica Volk | Director, Strategy & Insight | Leadership |
Laura Schreder | Country & Site Communications Lead - EMEA | Head Of Site Communications Marburg | Leadership |
Paul McKenzie | CEO | Leadership |
Dr. Michael Plater | Senior Director, Global Business Development & Licensing | Leadership |
Joel Hanson | Head Of Project Delivery, US | Leadership |
Chris Larkins | Senior Vice President Operations | Leadership |
Michael Bien | Senior Director Project Management | Leadership |
Elyse Muñoz | Associate Director, Market Intelligence | Leadership |
Leslie Bannon | Enterprise Head Of Alliances | Leadership |
Sue Thorn | Senior Manager, Communications Business Partner For R&d, Vaccines | Leadership |
Philippe Hebert | General Manager | Leadership |
Lukas Limbach | Director, Operations And International Demand Planning | Leadership |
Camilla Shen | Vice President Mid-size EMEA Markets | Leadership |
Kristina Harrison | Director, Pandemic Contracts North America | Leadership |
Fiona Mead | Company Secretary And Head Of Group Governance | Leadership |
405 more people are available in the full profile.
Complete people profiles for CSL Behring
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CSL Behring
CSL Behring has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Calimmune and Vitaeris.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Clazakizumab monoclonal antibody is developed for chronic inflammatory diseases. | vitaerisbio.com | Vancouver, Canada | 2016 | Jun 2020 | •••• | |
Developer of autologous cell therapies to enhance immune response for infectious diseases | calimmune.com | Tucson, United States | 2006 | Aug 2017 | $91M |
Complete acquisition details for CSL Behring
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of CSL Behring
The website of CSL Behring (cslbehring.com) receives about 78.2K visits a month and ranks #544,483 among all websites worldwide, #565 in Biotechnology and Pharmaceuticals.
- Monthly visits78.2K
▲ 48.7% vs previous month
- Unique visitors18.2K
per month
- Global rank#544,483
among all websites
- Category rank#565
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit3.3
- Average visit2 min 31 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with CSL Behring. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
csl.com.au | csl.com.au | 100% | – | – | – |
rinvoqhcp.com | rinvoqhcp.com | 94% | – | #1,291,015 | – |
pptaglobal.org | pptaglobal.org | 83% | – | #1,548,204 | – |
| merck.com | 82% | 656.8K | #78,842 | View details | |
aeternazentaris.com | aeternazentaris.com | 82% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 38 similar websites and full traffic analytics for CSL Behring
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 38 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Csl Behring
Complete news archive for CSL Behring
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to CSL Behring
10 companies that operate in the same segment as CSL Behring (Diversified Medical Devices), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medical equipment for treating over 30 chronic diseases is developed. | 1949 | Minneapolis, Minnesota, United States | – | USD 36.36 B | 95,000 | |
Wide range of medical devices | 1979 | Marlborough, Massachusetts, United States | – | USD 20.07 B | 53,000 | |
Healthcare solutions are provided by Johnson & Johnson globally. | 1886 | New Brunswick, New Jersey, United States | – | USD 94.18 B | 139,800 | |
Diagnostic and surgical products for women's healthcare are provided. | 1985 | Marlborough, Massachusetts, United States | – | USD 4.1 B | 7,060 | |
Developer of drug candidates for the treatment of rare CNS disorders | 1971 | Boston, Massachusetts, United States | USD 105.8 M | – | 487 | |
Surgical instruments are manufactured for multiple therapeutic areas. | 1987 | Utica, New York, United States | – | USD 1.37 B | 3,900 | |
A wide range of medical devices is developed by HOYA. | 1941 | Tokyo, Tokyo, Japan | – | USD 5.94 B | 37,910 | |
Medical devices for cardiac and neuromodulation therapies are manufactured globally. | 1976 | Saint Paul, Minnesota, United States | – | – | – | |
Complex healthcare challenges are addressed through technology solutions by Commure. | 2016 | San Francisco, California, United States | USD 823.3 M | – | 316 | |
Provider of medical devices for emergency medicine and various health conditions | 1943 | Wayne, United States | – | USD 1.99 B | 14,100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CSL Behring
CSL Behring was founded in 2009 and raised its 1st funding round 11 years after it was founded.
CSL Behring is headquartered in King Of Prussia, United States. It is registered at King Of Prussia, Pennsylvania, United States.
CSL Behring is focused on the development, manufacture, and marketing of protein-based therapies for serious and chronic medical conditions. The company offers products in the area of Bleeding Disorders Therapies, Fluid Replacement Therapies, Hereditary Angioedema (HAE) Therapies, Immunoglobulin Therapies, Pulmonary Therapies, and Wound Healing Therapies. The products are used for the treatment of coagulation disorders including von Willebrand disease (VWD), hemophilia, primary immunodeficiency (PID), hereditary Angioedema (HAE), fibrinogen deficiency, genetic emphysema, and other rare diseases.
CSL Behring has 1 investor. Key investors include NIH.